Physician
Hematology
Dr. Kenneth H. Shain, MD
|
|
Give Review
Kenneth Shain is an expert in the field of Hematology. He attended University of South Florida College of Medicine. University of South Florida College of Medicine is ranked 79 in research and 85 in primary care medicine Kenneth Shain is also a published doctor. He has 26 paper published. The most recent paper is: Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Kenneth H. Shain, MD accepts all Medicare patients.
Publications
- Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.
- The tumor microenvironment shapes hallmarks of mature B-cell malignancies.
- An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.
- Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome.
- A preclinical assay for chemosensitivity in multiple myeloma.
- The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies.
- Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.
- Sequence of novel agents in multiple myeloma: An instrumental variable analysis.
- High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation.
- Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
- Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow.
- Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myel...
- Monitoring a nuclear factor-kappaB signature of drug resistance in multiple myeloma.
- Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Expe...
- Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
- Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.
- Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
- Regulation of caspase expression and apoptosis by adenomatous polyposis coli.
- Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-ind...
- Deletions of Xp22.2 including PIG-A locus lead to paroxysmal nocturnal hemoglobinuria.
- Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP.
- Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects.
- Targeting the bone marrow microenvironment in hematologic malignancies.
- Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.
- Environmental-mediated drug resistance: a target for multiple myeloma therapy.
Schools
University of South Florida College of Medicine
University Of South Florida
Doctors Specialties
- Internal Medicine
- Hematology
Accepted Insurances
Education
-
University of South Florida -
University of South Florida College of Medicine
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1083809255 | |
| NPPES Provider LastName | SHAIN | |
| NPPES Provider FirstName | KENNETH | |
| NPPES Provider ZIPCode | 336063508 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 274.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 19.0 | |
| Percent Opioid Claims | 6.93 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083809255 |
| Last Name Of The Provider | SHAIN |
| First Name Of The Provider | KENNETH |
| View All |
Similar Doctors
|
Dr. Erika S. Abel, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Victor Valentin, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jennifer Cultrera, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anh P. Nguyen, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Carlos Palacio, MD |
|
|
Dr. James A. Follett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John B. Hampton, MD |
|
Dr. Yasir Alhassani, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ron D. Schiff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Halajko, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Tawee Tanvetyanon, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Magda E. Melchert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark S. Robbins, MD |
|
Dr. Rami S. Komrokji, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Teresa L. Field, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pamela B. Wilson, MD
This Doctor is OpenDoctor Recommended.
|